Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1Research in context

Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1Research in context

Background: A newly developed drug trastuzumab emtansine (T-DM1) has improved the survival of breast cancer (BC) patients. Despite an impressive initial clinical response, a subgroup of patient develop resistance and present therapeutic challenges. The underlying resistance mechanisms are not fully...

Full description

Bibliographic Details
Main Authors: Syed S. Islam, Mohammed Uddin, Abu Shadat M. Noman, Hosneara Akter, Nusrat J. Dity, Mohammad Basiruzzman, Furkan Uddin, Jahanara Ahsan, Sunera Annoor, Ayodele A. Alaiya, Monther Al-Alwan, Herman Yeger, Walid A. Farhat
Format: Article
Language:English
Published: Elsevier 2019-05-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396419303007

Internet

http://www.sciencedirect.com/science/article/pii/S2352396419303007

Similar Items